Andrx Labs Llc Drug Patent Portfolio
Andrx Labs Llc owns 1 orange book drug protected by 6 US patents Given below is the list of Andrx Labs Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6790459 | Methods for treating diabetes via administration of controlled release metformin | 17 Mar, 2021 | Expired |
| US6866866 | Controlled release metformin compositions | 17 Mar, 2021 | Expired |
| US6099859 | Controlled release oral tablet having a unitary core | 20 Mar, 2018 | Expired |
| US6495162 | Controlled release oral tablet having a unitary core | 20 Mar, 2018 | Expired |
| US7919116 | Controlled release metformin formulations | 20 Mar, 2018 | Expired |
| US8475841 | Controlled release metformin formulations | 20 Mar, 2018 | Expired |
Latest Legal Activities on Andrx Labs Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Andrx Labs Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 May, 2023 | US7919116 |
|
Maintenance Fee Reminder Mailed
Critical
| 21 Nov, 2022 | US7919116 |
|
Expire Patent
Critical
| 09 Aug, 2021 | US8475841 |
|
Maintenance Fee Reminder Mailed
Critical
| 22 Feb, 2021 | US8475841 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Sep, 2018 | US7919116 |
| File Marked Found | 09 Nov, 2016 | US6495162 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Jul, 2013 | US8475841 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Jul, 2013 | US8475841 |
|
Issue Notification Mailed
Critical
| 12 Jun, 2013 | US8475841 |
| Dispatch to FDC | 07 Jun, 2013 | US8475841 |
| Mail Miscellaneous Communication to Applicant | 30 May, 2013 | US8475841 |
| Printer Rush- No mailing | 26 May, 2013 | US8475841 |
| Miscellaneous Communication to Applicant - No Action Count | 26 May, 2013 | US8475841 |
|
Pubs Case Remand to TC
Critical
| 23 May, 2013 | US8475841 |
|
Application Is Considered Ready for Issue
Critical
| 22 May, 2013 | US8475841 |
Andrx Labs Llc's Drug Patent Litigations
Andrx Labs Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 23, 2017, against patent number US6790459. The petitioner Aurobindo Pharma USA Inc., challenged the validity of this patent, with Andrx Labs, LLC as the respondent. Click below to track the latest information on how companies are challenging Andrx Labs Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6866866 | June, 2017 |
FWD Entered
(28 Dec, 2018)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
| US6790459 | January, 2018 |
Terminated-Denied
(05 Sep, 2018)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
| US6790459 | June, 2017 |
Terminated-Denied
(29 Dec, 2017)
| Andrx Labs, LLC | Aurobindo Pharma USA Inc. |
Andrx Labs Llc's Family Patents
Andrx Labs Llc Drug List
Given below is the complete list of Andrx Labs Llc's drugs and the patents protecting them.
1. Fortamet
Fortamet is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6790459 | Methods for treating diabetes via administration of controlled release metformin |
17 Mar, 2021
(3 years ago)
| Expired |
| US6866866 | Controlled release metformin compositions |
17 Mar, 2021
(3 years ago)
| Expired |
| US6099859 | Controlled release oral tablet having a unitary core |
20 Mar, 2018
(6 years ago)
| Expired |
| US6495162 | Controlled release oral tablet having a unitary core |
20 Mar, 2018
(6 years ago)
| Expired |
| US7919116 | Controlled release metformin formulations |
20 Mar, 2018
(6 years ago)
| Expired |
| US8475841 | Controlled release metformin formulations |
20 Mar, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fortamet's drug page